The present invention relates generally to the field of pharmaceuticals, and specifically relates to isofagomine (IFG), novel salts thereof and preparation methods and uses of these, for example, in formulating pharmaceutical compositions for the treatment of Gaucher disease. Also provided are novel crystalline forms of isofagomine salts, methods for preparing the crystalline forms, and their use in formulating pharmaceutical compositions.

Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.

A resist composition containing a resin component having a structural unit represented by general formula (a0-1), and a compound represented by general formula (b1). In general formula (a0-1), R is a hydrogen atom, an alkyl group, or a halogenated alkyl group. Va.sup.1 is a divalent hydrocarbon group. n.sub.a1 represents an integer of 0 to 2. Ra′.sup.12 and Ra′.sup.13 are a monovalent chain saturated hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom. Ra′.sup.14 is a phenyl group, a naphthyl group, or an anthryl group. In general formula (b1), R.sup.b1 represents a cyclic hydrocarbon group. Y.sup.b1 represents a divalent linking group containing an ester bond. V.sup.b1 represents an alkylene group, a fluorinated alkylene group, or a single bond. m is an integer of 1 or more, and M.sup.m+ is an m-valent organic cation.

##STR00001##

A resist composition containing a resin component having a structural unit represented by general formula (a0-1), and a compound represented by general formula (b1). In general formula (a0-1), R is a hydrogen atom, an alkyl group, or a halogenated alkyl group. Va.sup.1 is a divalent hydrocarbon group. n.sub.a1 represents an integer of 0 to 2. Ra′.sup.12 and Ra′.sup.13 are a monovalent chain saturated hydrocarbon group having 1 to 10 carbon atoms or a hydrogen atom. Ra′.sup.14 is a phenyl group, a naphthyl group, or an anthryl group. In general formula (b1), R.sup.b1 represents a cyclic hydrocarbon group. Y.sup.b1 represents a divalent linking group containing an ester bond. V.sup.b1 represents an alkylene group, a fluorinated alkylene group, or a single bond. m is an integer of 1 or more, and M.sup.m+ is an m-valent organic cation.

##STR00001##

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

A monomer having an onium salt structure represented by formula (1) gives a polymer which is fully compatible with resist components. A resist composition comprising the polymer has advantages including reduced acid diffusion, high sensitivity, high resolution, a good balance of lithography properties, and less defects, and is quite effective for precise micropatterning.

##STR00001##

A monomer having an onium salt structure represented by formula (1) gives a polymer which is fully compatible with resist components. A resist composition comprising the polymer has advantages including reduced acid diffusion, high sensitivity, high resolution, a good balance of lithography properties, and less defects, and is quite effective for precise micropatterning.

##STR00001##

In one aspect, the invention relates to substituted 6-amino-5,8-dioxo-5,8-dihydronaphthalene-1-sulfonamide analogs and derivatives thereof, substituted 4-amino-5H-naphtho[1,8-cd]isothiazol-5-one 1,1-dioxide analogs and derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

In one aspect, the invention relates to substituted 6-amino-5,8-dioxo-5,8-dihydronaphthalene-1-sulfonamide analogs and derivatives thereof, substituted 4-amino-5H-naphtho[1,8-cd]isothiazol-5-one 1,1-dioxide analogs and derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

A composite organic compound characterized by polarizability and resistivity that has a general structural formula: where C is a chromophore fragment, P is an optionally connected rylene fragment, D and A are electron donating and accepting groups respectively, and R represents resistive substituents optionally connected directly or via dopant connecting groups.